🇺🇸 FDA
Pipeline program

Paracetamol/Codeine phosphate hemihydrate Accord 500 mg/30 mg tablets, PARACETAMOL, DFV890, Placebo to DFV890 10mg, Placebo to DFV890 25mg, DFV890

CDFV890B12201

Phase 2 small_molecule active

Quick answer

Paracetamol/Codeine phosphate hemihydrate Accord 500 mg/30 mg tablets, PARACETAMOL, DFV890, Placebo to DFV890 10mg, Placebo to DFV890 25mg, DFV890 for Knee Osteoarthritis is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Knee Osteoarthritis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials